A 14-woman pilot assessed vaginal tissue after radiofrequency treatment. Understand its findings, limits and questions for menopause care.
On October 13, 2026, The Menopause Society reported a Brazilian pilot study of microablative fractional radiofrequency (MFRF) in 14 postmenopausal women. The participants had genitourinary syndrome of menopause (GSM). The research focused on vaginal tissue measurements rather than whether sexual discomfort or other symptoms improved.
That focus matters when reading a headline about a procedure for menopause-related discomfort. A study of tissue structure asks a different question from a study of daily comfort. The Society’s announcement offers an early look at a proposed biological effect. Understanding what the researchers measured is the starting point for deciding how much weight to give the findings.
According to The Menopause Society, the researchers assessed vaginal epithelial morphometry and stromal collagen after MFRF. In plain language, their focus was on tissue dimensions and collagen characteristics. The reported findings concerned vaginal epithelial thickness and the size of collagen fibers in the tissue.
The population was specific: postmenopausal women with GSM. The Society describes GSM as involving genital changes, sexual discomfort and urinary issues. That makes the condition relevant to sexual wellbeing while also placing it beyond sexual concerns alone.
The release describes MFRF as delivering controlled thermal energy to vaginal tissue. This creates microscopic zones of injury intended to stimulate tissue remodeling and collagen production. That is the proposed mechanism behind the procedure. It explains why researchers would investigate tissue measurements after treatment.
The Society said additional details were scheduled for presentation at its 2026 Annual Meeting in San Diego. The October 13 announcement was therefore a report of preliminary findings ahead of a conference presentation. It should be read as that kind of research update rather than as a completed account of the procedure’s clinical role.
The Menopause Society reported two trends after treatment:
Neither change was statistically significant.
The distinction between an observed direction and a statistically significant finding is important. The researchers reported an upward pattern in the measurements. They did not report a statistically significant increase in either measure. Describing the results accurately means keeping both parts of that account together.
A headline saying that radiofrequency “increases collagen” would leave out the central qualification in the Society’s report. Equally, describing the study as finding no change in any participant would go beyond what was reported. The supported finding is narrower: the pilot observed trends in tissue measurements without statistically significant results.
Several limitations shape the interpretation. The sample was small, and the Society reported substantial variation among participants. Those features restrict how confidently the findings can describe a consistent tissue response or identify which women might respond.
This was a procedure-based pilot examining tissue after an intervention. The Society says it was not designed to demonstrate clinical effectiveness. It did not assess whether participants’ sexual discomfort or other GSM symptoms improved. The tissue findings therefore do not establish relief of vaginal dryness, pain during sex or urinary concerns.
The Society calls for larger controlled studies to confirm the findings and identify potential responders. Controlled research is important for assessing whether a measured change can be attributed to an intervention rather than other influences. The announcement does not establish that causal link.
The release quotes Dr. Stephanie Faubion, The Menopause Society’s medical director, emphasizing that further research is needed to understand the therapy’s role. Her interpretation places the pilot within an ongoing research process rather than treating it as evidence supporting routine treatment.
The results also belong to this specific MFRF pilot. They should not be extended to all radiofrequency devices or other energy-based procedures. Outcomes for different protocols and patient groups are separate questions. Long-term benefits and risks cannot be inferred from these tissue findings either.
The Society places GSM management in a broader context than this one procedure. Its release lists several approaches:
That management overview and the pilot serve different purposes. The overview identifies options for addressing GSM. The pilot investigates a biological question about vaginal tissue after a specific intervention. Reading them side by side helps prevent a preliminary procedure report from becoming the whole conversation about menopause-related discomfort.
The list is not a ranking of treatments or a statement that every option is equally suitable for every person. Questions about suitability belong in an individual clinical discussion. Sexential’s overview of different approaches to menopausal sexual symptoms provides a related educational starting point for understanding that broader conversation.
The Society’s description of GSM also helps keep the focus on the concern being addressed. Genital changes, sexual discomfort and urinary issues are related parts of its scope. A discussion about one symptom should remain connected to that symptom rather than being replaced entirely by language about collagen or tissue remodeling.
For readers seeking context beyond a procedure headline, this coverage of genital and urinary changes after menopause is relevant background. The purpose is to understand the subject more clearly, not to identify a treatment from an article or assume that a change in sexual experience has one explanation.
The practical significance of this update is an evidence-reading principle: the outcome being measured should match the benefit being discussed. A tissue measurement belongs in a conversation about tissue. A claim about comfort or sexual function requires evidence addressing those experiences.
Menopause-related discomfort deserves discussion with a qualified clinician. That conversation does not have to begin with a decision for or against a procedure. It can begin with the actual concern and the evidence relevant to it.
When vaginal radiofrequency is proposed, useful questions include:
These are questions for understanding evidence, not instructions to choose or reject treatment. Personal decisions require qualified care. A research announcement can help frame the conversation without making that decision on a reader’s behalf.
It is also useful to distinguish the language of a study from the language of a treatment claim. “Intended to stimulate remodeling” describes a rationale. “Observed a trend” describes a result. “Improved symptoms” describes a patient outcome. Those statements answer different questions and should not be substituted for one another.
For future research, the Society’s call for larger controlled studies gives readers a clear point to watch. More informative reporting would connect the study design with the outcomes being assessed. Readers interested in comfort and sexual function can keep those outcomes central when considering any later findings.
The October 13 announcement put vaginal tissue measurements in the foreground. The wider view keeps those measurements beside the human question that gives them practical meaning: what improvement in comfort or sexual wellbeing has actually been demonstrated? That perspective gives a preliminary research report its proper place without turning it into a treatment decision.
When vaginal radiofrequency enters a treatment discussion, identifying which findings address comfort becomes the priority; Sexential supports that understanding through evidence-aware sexual wellness education. Readers uncertain about what influences sexual function can find explanations linking biology with relationships and aging, written for adults aged 35 to 65 without personalised medical advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
